Anti-Rheumatic Drugs - Turkmenistan

Turkmenistan

The Anti-Rheumatic Drugs market in Turkmenistan is anticipated to witness a substantial increase in revenue, with projections indicating a staggering US$8.94m in 2024.
This growth is expected to continue at a steady pace, with an estimated annual growth rate (CAGR 2024-2029) of 2.08%.
By 2029, the market volume is predicted to reach an impressive US$9.91m.
When compared on a global scale, it is noteworthy that United States is expected to generate the highest revenue in this market, with a staggering US$34,700.00m in 2024.
Turkmenistan's demand for anti-rheumatic drugs is steadily increasing due to a growing aging population and rising prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Turkmenistan has been steadily growing over the past few years.

Customer preferences: As the population of Turkmenistan ages, the demand for Anti-Rheumatic Drugs has increased. This is due to the fact that Rheumatoid Arthritis and other rheumatic diseases are more common in older individuals. Additionally, there is a growing awareness of these diseases and their symptoms, leading more people to seek treatment.

Trends in the market: One trend in the Anti-Rheumatic Drugs market in Turkmenistan is the increasing use of biologic drugs. These drugs are more targeted and effective than traditional disease-modifying anti-rheumatic drugs (DMARDs), and are becoming more widely available in the country. Another trend is the growing use of combination therapy, where multiple drugs are used together to treat rheumatic diseases.

Local special circumstances: Turkmenistan has a state-run healthcare system, which means that the government is heavily involved in regulating the pharmaceutical industry. This can make it difficult for foreign companies to enter the market, as they must navigate complex regulations and bureaucratic hurdles. As a result, the Anti-Rheumatic Drugs market in Turkmenistan is dominated by local companies.

Underlying macroeconomic factors: Turkmenistan is a relatively wealthy country, with a high GDP per capita compared to many of its neighbors. This has allowed for increased investment in healthcare infrastructure, including hospitals and clinics that can provide treatment for rheumatic diseases. Additionally, the government has made efforts to improve access to healthcare for rural populations, which has helped to increase demand for Anti-Rheumatic Drugs in these areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.